Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.

Literature DB >> 3518359

Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.

R Mastacchi, M Barbanti, P Bianchini, B Osima.

Abstract

In vitro platelet proaggregating effect of unfractionated heparin (H) and OP/LMWH were studied with human platelets. OP/LMWH produced a significant less potentiation of ADP and PAF induced aggregation and slightly counteracted the antiaggregating effect of PGI2, in comparison with H. The proaggregating effect of both heparins was neutralized by equal contemporaneous amount of protamine sulfate.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1986 PMID： 3518359 DOI： 10.1007/bf01965523

Source DB: PubMed Journal: Agents Actions ISSN： 0065-4299

15 in total

Review 1. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).

Authors: J M Walenga; J Fareed; D A Hoppensteadt
Journal: Semin Thromb Hemost Date: 1985-01 Impact factor: 4.180

Review 1. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.

Authors: J E Frampton; D Faulds
Journal: Drugs Date: 1994-04 Impact factor: 9.546

1 in total

Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.

Review 1. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).

2. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.

3. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin.

4. Interaction of heparin and heparin fractions with human platelets.

Review 5. Effect of heparin and heparin fractions on platelet aggregation.

6. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.

7. Normal and low molecular weight heparins: interaction with human platelets.

8. Neutralisation of heparan sulphate and low molecular weight heparin by protamine.

9. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation.

10. Molecular events involved in the proaggregating effect of heparin on human platelets.

Review 1. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.